The Key Person Clause: What Actually Protects You If Your Fund Manager Walks Away

Most LPs invest in a fund because of two or three specific people, and almost none of them read the clause that protects them if those people leave, according to the SEC's own investor education resources on private fund due diligence. I've sat through enough fund closings to know how this plays out: the pitch deck leads with the track record, the track record leads with two names, and the limited partnership agreement (the LPA, the master contract governing the fund) sits in a data room nobody opens past the fee schedule. The key person clause is buried in there, usually between the indemnification section and the transfer restrictions, and it's the single provision that tells you what happens if the person you're actually betting on walks out the door, gets hit by a bus, or just stops showing up.

This guide explains what a key person clause (sometimes written "key man clause," an older term still used interchangeably) actually does, what happens when one triggers, how the language is typically structured, where it falls short, and how to read one before you wire capital.

What a Key Person Clause Actually Protects

A key person clause names specific individuals in a fund's governing documents, usually the founding partners or the lead portfolio managers, and defines a consequence if those individuals stop being sufficiently involved in the fund. The names are not incidental. They're the entire reason many LPs signed the subscription agreement in the first place.

Here's the distinction that matters. When you underwrite a venture fund or a private credit vehicle, you're told you're buying into a strategy: seed-stage B2B software, distressed real estate debt, lower-middle-market buyouts. But a stated strategy on paper doesn't generate returns by itself. Two General Partners running the same stated strategy with the same fund size can produce wildly different outcomes, because sourcing, underwriting judgment, and portfolio triage are exercised by particular humans with particular networks and particular pattern recognition. You are, in practice, underwriting people wearing a strategy as a label. The Institutional Limited Partners Association (ILPA), the industry body that publishes model LPA terms and best-practice principles for institutional LPs, treats key person provisions as a baseline governance term precisely because the gap between "the strategy" and "the people running the strategy" is where LP capital is most exposed. ILPA's guidance pushes for these provisions to be standard in any fund raising from institutional capital, not a negotiated extra.

A GP is the general partner: the entity (and the people behind it) that manages the fund, makes investment decisions, and calls capital from LPs, the limited partners who supply the money but have no say in day-to-day decisions. That asymmetry is exactly why LPs need contractual protection instead of operational control. You can't fire the analyst who's souring on the job. You can, if the LPA is written correctly, freeze the fund's ability to spend more of your money until the people you backed either come back or get replaced by someone the LPs approve.

What Happens When the Clause Triggers

A key person event doesn't dissolve the fund and it doesn't return your money. It suspends forward motion. The most common consequence is an automatic suspension of the investment period (the window, typically three to six years, during which the GP is allowed to call capital and make new investments). Once triggered, the GP loses the ability to call more capital or close new deals until one of two things happens: the LPs vote to waive the provision and let the GP keep operating as before, or the GP proposes a replacement key person and the LPs approve.

During a suspension, the fund typically can still manage the existing portfolio: follow-on investments in current holdings are often carved out, and the GP keeps collecting management fees, though some LPAs step the fee down during a suspension period. What stops is expansion: no new platform investments, no new capital calls tied to unfunded commitments. Some LPAs go further and give LPs a right to terminate the investment period outright, ending the fund's ability to deploy new capital permanently rather than temporarily, or a right to remove the GP for cause, meaning removal tied to a defined bad act or failure (fraud, gross negligence, material breach) rather than a no-fault vote. For-cause removal is a much higher bar than a key person suspension and usually requires a supermajority LP vote, sometimes 66% or 75% of commitments. Law firms that handle fund formation, including Kirkland & Ellis and Ropes & Gray, negotiate this exact menu of remedies on both sides of the table every fundraising cycle, and the range of what ends up in a final LPA is wide enough that you cannot assume any one outcome without reading the actual text.

Trigger Type	What It Means	Typical Remedy
Departure	Named person resigns or is terminated from the GP	Automatic investment period suspension
Death or disability	Named person dies or becomes permanently incapacitated	Automatic suspension, often faster cure timeline
Reduced time commitment	Named person falls below a defined business-time threshold (e.g., under 51%)	Suspension after a notice and cure period
Multiple key person departures	More than the minimum number of named individuals leave	Suspension, sometimes escalating to LP termination right
For-cause conduct	Fraud, gross negligence, willful misconduct, material breach	GP removal, subject to supermajority LP vote

How Key Person Provisions Are Actually Structured

Every well-drafted key person clause has three moving parts, and you need to check all three, because a strong version of one part can be undercut by a weak version of another.

The named individuals and the minimum threshold

The LPA names a specific list of people, sometimes two, sometimes five or six, and specifies a minimum number who must remain "actively involved" for the fund to keep operating normally. A fund that names five people but only requires two to stay active is functionally protecting you far less than the headline list suggests. Read the threshold, not the roster.

The time-commitment definition

"Actively involved" gets defined with a business-time percentage, commonly a requirement that each named person devote something like 51% or more of their professional business time to the fund (or to the GP's fund family, if the manager runs multiple vehicles). This is where multi-fund managers create ambiguity: a person can satisfy a 51% test while splitting attention across three active funds, and LPs in any single one of those funds may reasonably wonder how much of that person's judgment is actually available to their capital specifically.

The cure period

Almost no LPA triggers a suspension with zero recourse for the GP. Instead, there's a cure period, a window (commonly 90 to 180 days) during which the GP can propose a replacement key person for LP approval, or otherwise remedy the trigger, before the suspension becomes a longer-term or permanent state. Cure periods exist because LPs generally don't want to blow up a fund over one departure if a credible successor is available. They want a structured off-ramp, not a cliff. Debevoise & Plimpton's fund formation practice, like most large firms in the space, will tell you the negotiation over cure period length and replacement-approval thresholds is often more contested than the existence of the key person clause itself, because that's where the real use sits.

Where Key Person Clauses Fall Short

I want to be direct about the limits here, because a lot of LPs treat a key person clause as a solved problem once it's in the document, and it isn't. First, a key person clause protects against a defined event: departure, death, disability, or a measurable drop below a time-commitment threshold. It does not protect against disengagement that never crosses those lines. A founder can stay on the letterhead, keep clearing the 51% time test on paper, and still be checked out: distracted by a new venture, coasting on reputation, delegating underwriting to a team the LPs never diligenced. None of that trips a formally drafted trigger. This is the most common gap I see, and it's structural, not a drafting mistake — you cannot write a contract clause around "lost the fire in the belly."

Second, funds built around a single dominant personality carry concentration risk that a key person clause only partially addresses. If the LPA names one person and requires that one person to stay active, a departure trigger does eventually fire — but by the time it does, the fund may have already lost the judgment that mattered most, and a suspension freezes forward deployment without undoing whatever damage occurred during a slow decline in engagement. A deeper bench, several named individuals with real decision authority, is a better structural hedge than a strong clause wrapped around one name.

Third, enforcement disputes are real. What counts as "actively involved" or "51% of business time" is rarely audited in real time, and GPs and LPs have disagreed after the fact about whether a threshold was actually breached, particularly when a key person moved into an advisory or reduced-operating role without a clean resignation. Time-commitment thresholds are self-reported in practice. There's no clock running on anyone's calendar that the LPs can independently verify. The SEC's guidance on private placement due diligence emphasizes reviewing governance terms precisely because these disputes tend to surface in arbitration or side letters rather than in headlines, and a lot of them get resolved quietly with a negotiated waiver rather than a public fight.

How to Evaluate a Key Person Clause Before You Commit Capital

Use this checklist against the actual LPA or PPM (private placement memorandum, the offering document that discloses fund terms and risks to prospective investors) before you sign a subscription agreement, not after.

1. Get the named list. Ask the GP directly, in writing, which individuals are named as key persons in the LPA. If the answer is vague or takes more than a day to produce, that's information too.
2. Check the minimum threshold against the named list. If five people are named but only two must stay active, treat the fund as effectively protected by two people, not five.
3. Find the time-commitment definition. Look for the specific percentage and whether it's measured against this fund alone or against the GP's entire platform, including other funds the same team manages.
4. Read the trigger-to-remedy path. Does a trigger suspend the investment period automatically, or does it just create a right for LPs to call a vote? Automatic suspension protects you by default; a vote-only mechanism means you need enough allied LPs to act.
5. Check the cure period length and replacement approval threshold. A 180-day cure with a simple-majority replacement approval is very different from a 60-day cure requiring 75% LP approval.
6. Ask what percentage of the track record sits with the named people. If the fund's marketed returns come almost entirely from deals sourced or led by one of the named individuals, the concentration risk is higher than the clause alone can fix.
7. Ask about bench depth beyond the named persons. Who actually runs underwriting and portfolio management day to day if a key person is out for six months, cure period or not?
8. Compare the language to ILPA's model terms. ILPA publishes governance principles that many institutional LPs use as a baseline; a fund whose key person language falls noticeably short of that baseline should prompt a direct question to the GP about why.

None of this takes more than an afternoon if you already have the LPA in hand, and most GPs raising from sophisticated LPs expect these questions. A GP who resists a direct question about who's named and what threshold applies is telling you something about how they'll behave the next time a real key person event happens.

The clause is not a guarantee. It's a floor. It stops the GP from calling more of your capital blind after something has gone wrong with the people you actually underwrote, and it gives LPs a structured process instead of an ad hoc scramble. What it can't do is replace your own judgment about how concentrated the fund's success really is in one or two names, and how deep the bench sits underneath them. Read the clause before you wire the capital, not after the person you backed has already left.

Author Disclosure: Jeff Barnes, MBA has no personal position in any company, fund, or platform named in this article. Angel Investors Network has no current commercial relationship with any party mentioned. AIN provides marketing and education services, not investment advice. Past performance does not guarantee future results. All investments involve risk, including loss of principal.